Anatomic Stage IV Breast Cancer AJCC v8 Clinical Trials

50 recruitingLast updated: June 17, 2026

There are 50 actively recruiting anatomic stage iv breast cancer ajcc v8 clinical trials across 6 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Columbus, Ohio, United States, St Louis, Missouri, United States, Oklahoma City, Oklahoma, United States. Updated daily from ClinicalTrials.gov.


Anatomic Stage IV Breast Cancer AJCC v8 Trials at a Glance

50 actively recruiting trials for anatomic stage iv breast cancer ajcc v8 are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 25 trials, with the heaviest enrollment activity in Columbus, St Louis, and Oklahoma City. Lead sponsors running anatomic stage iv breast cancer ajcc v8 studies include National Cancer Institute (NCI), Mayo Clinic, and City of Hope Medical Center.

Browse anatomic stage iv breast cancer ajcc v8 trials by phase

Treatments under study

About Anatomic Stage IV Breast Cancer AJCC v8 Clinical Trials

Looking for clinical trials for Anatomic Stage IV Breast Cancer AJCC v8? There are currently 50 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Anatomic Stage IV Breast Cancer AJCC v8 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Anatomic Stage IV Breast Cancer AJCC v8 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 50 trials

Recruiting

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+3 more
Mayo Clinic230 enrolled1 locationNCT04517838
Recruiting
Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)32 enrolled10 locationsNCT05673200
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 2

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
Emory University37 enrolled2 locationsNCT05741164
Recruiting
Phase 2

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaRecurrent Breast Carcinoma
OHSU Knight Cancer Institute10 enrolled1 locationNCT04529044
Recruiting
Not Applicable

Intravital Microscopy in Human Solid Tumors

Malignant Brain NeoplasmMalignant Solid NeoplasmAnatomic Stage IV Breast Cancer AJCC v8+20 more
Mayo Clinic85 enrolled1 locationNCT03823144
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+6 more
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting
Phase 2

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Carcinoma in the Liver
City of Hope Medical Center11 enrolled1 locationNCT06860815
Recruiting
Phase 1Phase 2

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma
University of Washington22 enrolled1 locationNCT06502691
Recruiting
Not Applicable

Mobile Health for Adherence in Breast Cancer Patients

Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled506 locationsNCT06112613
Recruiting
Phase 1

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)57 enrolled6 locationsNCT05422794
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Metastatic Breast CancerAnatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor-positive Breast Cancer+1 more
Mayo Clinic35 enrolled1 locationNCT06525766
Recruiting
Phase 2

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8+1 more
Roswell Park Cancer Institute23 enrolled3 locationsNCT04348747
Recruiting
Phase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+2 more
NRG Oncology115 enrolled58 locationsNCT06500481
Recruiting
Phase 1Phase 2

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Yuan Yuan34 enrolled1 locationNCT05318469